PT  - JOURNAL ARTICLE
AU  - A.R. Sepahdari
AU  - N. Vorasubin
AU  - G. Ishiyama
AU  - A. Ishiyama
TI  - Endolymphatic Hydrops Reversal following Acetazolamide Therapy: Demonstrated with Delayed Intravenous Contrast-Enhanced 3D-FLAIR MRI
AID  - 10.3174/ajnr.A4462
DP  - 2015 Sep 17
TA  - American Journal of Neuroradiology
4099  - http://www.ajnr.org/content/early/2015/09/17/ajnr.A4462.short
4100  - http://www.ajnr.org/content/early/2015/09/17/ajnr.A4462.full
AB  - SUMMARY: Endolymphatic hydrops, the primary pathologic alteration in Menière disease, can be visualized by using delayed intravenous contrast-enhanced 3D-FLAIR MR imaging. It is not known whether MR imaging–demonstrable changes of hydrops fluctuate with disease activity or are fixed. We describe the results of baseline and posttreatment MR imaging studies in a group of subjects with Menière disease with hydrops who were treated with acetazolamide. Seven subjects with untreated Menière disease with MR imaging evidence of hydrops had repeat MR imaging during acetazolamide treatment. Symptoms and imaging findings were assessed at each time point. Five subjects showed symptom improvement, of whom 3 had improvement or resolution of hydrops. One subject had recurrent symptoms with recurrent hydrops after discontinuing therapy. Two had unchanged hydrops despite symptom improvement. Subjects with unchanged symptoms had unchanged hydrops. Hydrops reversal may be seen with acetazolamide treatment in Menière disease. MR imaging may provide an additional biomarker of disease.AbbreviationshT2WI-FLAIRheavily T2-weighted 3D FLAIRMDMenière diseaseSPACEsampling perfection with application-optimized contrasts by using different flip angle evolutions